MMTX — MindMaze Therapeutics Holding SA Share News
0.000.00%
Last trade - 00:00- CH₣34.12m
- CH₣24.65m
- CH₣0.64m
Brief: Relief Therapeutics names new CEO, CFO
Swiss stocks - Factors to watch on November 16
Brief: Relief Therapeutics Holding SA Adds H.C. Wainwright & Co As Underwriter To IPO - SEC Filing
Brief: Relief Therapeutics Holding And Nrx Pharmaceuticals Announce Execution Of Definitive Settlement Agreements
Brief: Acer Therapeutics And Relief Therapeutics Announce Receipt Of Notice Of Allowance Of US Patent Application Covering A Kit Comprising Phenylbutyrate And Sodium Benzoate
Brief: Relief Therapeutics Holding SA Files For U.S. IPO - SEC Filing
Brief: Relief Therapeutics And NRX Announce Tentative Settlement Of Pending Litigation
Acer Therapeutics rises after gaining EU's 'orphan drug' tag
Brief: Relief Therapeutics, Acer Therapeutics Report EC Orphan Drug Tag For ACER-001
Brief: Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For Review Of NDA Resubmission For Treatment Of UCDS
Brief: Relief Therapeutics: Collaboration Partner Resubmits Acer-001 (Sodium Phenylbutyrate) New Drug Application (NDA) To FDA
Brief: Relief Therapeutics Appoints Serene Forte As Senior Vice President
Swiss stocks - Factors to watch on July 18
Brief: Relief Therapeutics Signs Definitive Agreement To Acquire Novel Dosage Form For Treatment Of PKU
Brief: Acer Therapeutics And Relief Therapeutics Announce That The China National Intellectual Property Administration Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form
Brief: Acer Therapeutics And Relief Therapeutics: China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent
Swiss stocks - Factors to watch on July 8
Brief: Relief Therapeutics Files Amendment No. 4 To Registration Statement On Form 20-F
Brief: Relief: U.S. Collaboration Partner Says FDA Declines Emergency Use Authorization For Aviptadil